Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
Advanced Solid Tumors
DRUG: cediranib (RECENTIN TM, AZD2171)
To assess the steady-state PK parameters of cediranib in the presence and absence of ketoconazole., PK assessments to be taken until Day 42. Days 7 and 10 PK parameters used to assess the primary variables.
Safety and tolerability of cediranib in the presence of ketoconazole by assessment of Adverse events (AEs) Laboratory findings,Vital signs, physical examination and Electrocardiogram., Until study drug is discountinued
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.